Categories: Research

How well do states’ policies address possible conflicts of interest of committee members who decide which drugs get Medicaid reimbursement? The question looms especially large as impending federal health care reform increases the number of patients covered by the state-run drug formularies.

Research at the UCSF School of Pharmacy to develop the first implantable bioartificial kidney recently received exceptional private support: $1 million from the family of the late philanthropists Harry and Diana Hind, and $50,000 from the Patterson Barclay Memorial Foundation.

An updated and expanded review of clinical research papers on drugs and medical devices finds that industry-sponsored studies are more likely to lead to favorable results, including reports of greater benefits and fewer harmful side effects.

Shuvo Roy, PhD, will be inducted on November 1st as a member of the BayBio Pantheon for his contributions to the life sciences industry and specifically for work developing the world’s first surgically implantable bioartificial kidney. The BayBio Pantheon, which currently has 52 elected members,...

It can take just the flick of a genetic switch for breast cells to kick-start the normally well-regulated process of growth seen in puberty, pregnancy, or the menstrual cycle—or the mutation of that switch to initiate the unchecked proliferation of cancer.

The effort to create the first implantable bioartificial kidney has received a $750,000 gift from the John and Marcia Goldman Foundation.

Xiaokun Shu, PhD, has been named a recipient of the 2012 National Institutes of Health (NIH) Director’s New Innovator award, which will provide up to $1.5 million in research funding over the next five years.

New research has found that the protein clathrin, well known as a building block of containers used to transport biological cargo inside cells, also plays a key role in helping cells divide properly.

Systematic reviews seek to answer key questions about the relative effectiveness and safety of medical interventions by selecting, combining, and critically evaluating the research in published medical literature.

Two years after launching as a pilot effort, an innovative graduate curriculum in translational medicine jointly offered by UCSF and UC Berkeley has received final approval from University of California President Mark Yudof as a master’s degree program.